Brucella melitensis prosthetic joint infection. by Flury, Domenica et al.
J. Bone Joint Infect. 2017, Vol. 2 
 
 
http://www.jbji.net 
136 
Journal of Bone and Joint Infection 
2017; 2(3): 136-142. doi: 10.7150/jbji.18408 
Short Research Communication 
Brucella melitensis prosthetic joint infection 
Domenica Flury1, Henrik Behrend2, Parham Sendi3, Matthias von Kietzell1, Carol Strahm1 
1. Department of Infectious Diseases, Cantonal Hospital of St. Gallen, St. Gallen; 
2. Department of Orthopaedics and Traumatology, Cantonal Hospital of St. Gallen, St. Gallen; 
3. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.  
 Corresponding author: Carol Strahm, M.D., Department of Infectious Diseases, Cantonal Hospital of St. Gallen, 9007 St. Gallen, Switzerland Tel. +41 71 494 26 
33 Fax. +41 71 494 63 39 Carol.Strahm@kssg.ch 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Published: 2017.04.05 
Abstract 
Periprosthetic joint infection (PJI) due to Brucella spp. is rare. We report a case in a 75-year-old 
man and review 29 additional cases identified in a literature search. The diagnosis of Brucella PJI is 
challenging, in particular in non-endemic countries. Serological tests prior to joint aspiration or 
surgical intervention are reasonable. Involvement of infection control and timely information to 
laboratory personnel is mandatory upon diagnosis. There is no uniform treatment concept, 
neither with respect to surgical intervention nor for the duration of antimicrobials. Most cases 
have a successful outcome, irrespective of surgical modality, and with an antimicrobial combination 
regimen for 12 or more weeks. 
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Intraduction 
Periprosthetic joint infection (PJI) due to Brucella 
is rare. We present a case of PJI due to Brucella 
melitensis and review the literature with respect to 
clinical presentation, diagnosis and treatment. 
Case Report 
A 75-year-old man from Turkey presented with a 
six-months history of progressing knee pain. His 
personal history included total right knee arthroplasty 
(TKA) because of osteoarthritis 12 years prior to, and 
one stage exchange due to aseptic loosening 4 years 
prior to admission. On presentation, radiographs of 
the right knee showed loosening of the prosthesis 
with migration of the tibial component (Figure 1a, b). 
Before referral to our center, B. melitensis grew in 
synovial fluid specimen obtained via arthrocentesis.  
The patient was born and raised in Turkey: He 
had moved to Switzerland at the age of 44. He 
reported to spend his summers in Turkey. There, he 
owns a house in a rural area, and commonly ingests 
fresh unpasteurized cheese and milk.  
On presentation, he was afebrile and no episodes 
of fever or night sweats were reported. Blood tests 
showed a C-reactive protein (CRP) of 18 mg/l 
(norm < 8 mg/l); leukocytes and thrombocytes were 
within normal range. Chest and lumbar radiographs, 
as well as abdominal ultrasound, were normal. Two 
sets of blood cultures remained negative. Serological 
test for antibodies against Brucella spp. were positive 
(IgG/IgA of 1:240 U/mL, normal < 20 U/ml; Brucella 
IgG/M/A Serion ELISA classic, SERION® 
Immunologics, Wuerzburg, Germany).  
A combined antimicrobial therapy consisting of 
doxycycline 100 mg twice per day and intravenous 
(IV) gentamicin 5 mg/kg once daily was started one 
week prior to surgery. The surgical plan included a 
two-stage exchange with a short interval. After 
removal of the implant, a mobile antibiotic loaded 
spacer (containing gentamicin and vancomycin) was 
implanted. Surgery was carried out under aerosol 
isolation precautions and laboratory personnel were 
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informed about possible risk of exposure. B. melitensis 
grew in 3, and Propionibacterium acnes in 4 out of 10 
obtained biopsies, sonication was negative. Thus, 
penicillin was added to the regimen (24 million units 
IV divided in 6 doses per day). After 2.5 weeks, a 
revision TKA was implanted (LCS Revision®, DePuy 
Synthes, Warsaw, IN). The further clinical course was 
uneventful. In the postoperative period, treatment 
with rifampin 450 mg twice per day was added, and 
gentamicin discontinued. Because P. acnes proved to 
be susceptible to doxycycline, treatment with 
penicillin was stopped and continued with 
doxycycline plus rifampin. Three months after 
surgery, monotherapy with doxycycline for another 
three months was prescribed. 
At the 2-year follow-up examination, the patient 
reported good joint function (ROM 0/5/105, 
WOMAC-Scale 12, VAS 80, EQ-5D 1) without clinical 
signs of infection. Radiographs showed a properly 
aligned TKA and no signs of loosening (Figure 1cd). 
 
 
Figure 1. Initial anteroposterior (a) and lateral (b) radiographs at referral showing a loose and displaced femoral and tibial component. Anteroposterior 
(c) and lateral (d) radiographs at follow-up 2 years after reimplantation. 
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Review of the Literature 
Methods 
For identifying published case reports, PubMed, 
PMC and Scopus databases were searched using the 
search string “Brucell* AND (prosth* OR replacement 
OR arthroplasty) AND (knee OR hip OR joint)”. 
Further a google query for “Brucella PJI” was 
performed. No restriction for time period of 
publications was applied. Two authors (DF and CS) 
reviewed titles and abstracts without restriction on 
date or language. Cases with symptoms consistent 
with PJI and Brucella spp. recovered from either 
synovial ﬂuid culture or biopsy samples were 
included.   
 
Table 1. Demographics and diagnostics 
Patient 
No 
Demographics Country of  
Exposure 
Involved 
Prosthesis 
Age of PJ 
(months) 
Previous 
Revisions 
Symptoms Cultures Brucella   
References 
Age & sex Exposure risk Species Aspiration Tissue Blood 
Culture 
Co- 
infection 
Serologies* 
1 24, f na Saudi Arabia TKR 
bilateral 
2 no local 
symptoms 
B. melitensis pos na na no pos 1 
2 72, m unpasteurized 
dairy products 
Turkey TKR 48 no local 
symptoms 
B. melitensis na pos neg no pos 2 (27) 
3 50, m farmer, cattle Spain THR 0 no systemic 
and local 
B. melitensis na pos pos no pos 3 
4 71, m farmer, cattle Spain THR 36 no local 
symptoms 
B. melitensis na pos na yes na 3 
5 67, f na Mexico THR 24 no local 
symptoms 
B. abortus neg pos na no na 4 (26) 
6 65, f unpasteurized 
dairy products 
Portugal TKR 
bilateral 
na no systemic 
and local 
B. melitensis neg pos na no na 5 
7 63, f unpasteurized 
dairy products 
Turkey TKR 24 yes systemic 
and local 
B. melitensis neg pos neg no pos 6 
8 71, f na Spain TKR 48 no systemic 
and local 
Brucella sp pos na na no pos 7 
9 68, f na Iran TKR 12 no local 
symptoms 
Brucella sp neg pos na no na 8 
10 54, m farmer United States THR 6 no systemic 
and local 
B. abortus neg pos na no pos 9 
11 62, m na Turkey TKR 24 no systemic 
and local 
B. melitensis pos na na no pos 10 
12 47, m unpasteurized 
dairy products 
Lebanon THR 168 no local 
symptoms 
Brucella sp na pos na no pos 11 
13 79, m contact with 
cattle 
Israel/ 
Argentina 
TKR 144 no local 
symptoms 
B. melitensis na pos na no na 12 
14 51, m contact with 
goats 
Thailand TKR 60 no systemic 
and local 
B. melitensis pos na pos no pos 13 
15 na unpasteurized 
dairy products 
India THR na na na B. melitensis pos na na na na 14 
16 74, m shepherd Greece TKR 
bilateral 
4 no systemic 
and local 
B. melitensis pos na pos no pos 15 
17 67, f unpasteurized 
dairy products 
Italy TKR 
bilateral 
48 no local 
symptoms 
Brucella sp neg pos na no na 16 
18 74, m unpasteurized 
dairy products 
Italy TKR 108 no local 
symptoms 
B. melitensis na pos na no pos 17 
19 65, f na Turkey TKR 
bilateral 
96 no systemic 
and local 
B. melitensis pos na na no pos 18 
20 63, m contact with 
cattle 
Spain THR 60 no local 
symptoms 
B. melitensis pos pos neg no na 19 
21 60, m contact with 
goats 
Spain TKR 14 no local 
symptoms 
B. melitensis pos na neg no pos 20 
22 66, f contact with 
cattle 
Spain THR 36 no local 
symptoms 
B. abortus pos na na no na 21 
23 71, m farmer, cattle Spain THR 63 yes  local 
symptoms 
B. melitensis na pos na no pos 21 
24 68, m na Italy TKR 24 no local 
symptoms 
B. melitensis pos na na no pos 22 
25 56, m farmer, sheep Spain THR 60 no systemic 
and local 
B. melitensis pos na neg no pos 23 
26 38, m unpasteurized 
dairy products 
Israel THR 48 no local 
symptoms 
B. melitensis neg pos na no pos 24 
27 61, m unpasteurized 
dairy products 
Israel TKR 36 yes  local 
symptoms 
B. melitensis pos pos na yes pos 24 
28 67, m unpasteurized 
dairy products 
Israel TKR 168 no systemic 
and local 
B. melitensis pos na na no pos 24 
29 64, f unpasteurized 
dairy products 
Turkey TKR 60 no local 
symptoms 
B. melitensis pos na na no pos 25 
30 75, m unpasteurized 
dairy products 
Turkey TKR 144 yes  local 
symptoms 
B. melitensis pos pos neg yes pos this case 
* Serum agglutination (=standard tube agglutination (SAT)) was used in most cases. Only positive results were quoted because of limited comparability among the different 
tests used; THR total hip replacement; TKR total knee replacement; PJ prosthetic joint; na not available. 
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Results 
The literature screening procedure is illustrated 
in Figure 2. Twenty-five published articles describing 
29 patients were identified [1-25] (Table 1). Three of 
them were co-infections. Two articles describing the 
same patients were excluded [26, 27]. 
Most patients were male and originated from 
southern Europe (Spain, Portugal, Italy, Portugal, 
Greece), or the Middle East (Turkey, Israel, Lebanon, 
Iran, Saudi Arabia). The majority reported a history 
that was congruent with the pathogenesis (e.g., 
regular consumption of unpasteurized dairy 
products, occupational exposure to animals). 
Eleven hip and 19 knee infections were 
described. The range of time interval between 
implantation of the prosthesis and the diagnosis of PJI 
was very broad (from immediately postoperative up 
to 168 months) with a median of 48 months. 62% 
(18/29) of patients had only local symptoms, and 38% 
(11/29) both systemic (mainly fever, malaise) and 
local symptoms. More than half of the patients (17/29) 
had a radiologically documented loosening of the 
implant. Twenty-three cases of B. melitensis, three of B. 
abortus and four cases of Brucella sp. were described. 
Diagnosis was mostly made by positive joint 
aspiration cultures (16/23). When no aspiration was 
performed (7/30) or aspiration culture was negative 
(7/23) intraoperative tissue biopsies were diagnostic. 
Only three cases had reported positive blood cultures. 
All cases with reported serology results revealed 
positive anti-Brucella antibodies (21/21). Three 
co-infections were documented, our case with P. acnes, 
one with viridans-group streptococci and one with 
Acinetobacter baumanii. In patients with radiological 
documented loosening, a one-stage exchange was 
performed in three, removal of the implant without 
replacement in one, and a two-stage exchange with a 
long interval (between 6 weeks and 6 months, median 
8 weeks) in 12 cases. In twelve patients without 
implant loosening, eight patients were treated 
conservatively (i.e. without surgery), two had a 
debridement with retention of the prosthesis and one 
had a one-stage and two-stage exchange, respectively. 
The outcome of all patients was reported as good. 
However, a follow up of a year or more was reported 
in only 23/30 cases (maximal 10 years, median 2 
years). Moreover, we cannot exclude a publication 
bias (i.e., only cases with a good outcome are 
reported). The antimicrobial regimen consisted of 
doxycycline and rifampin in most cases, with or 
without an aminoglycoside (streptomycin or 
gentamicin). In single cases quinolones or 
trimethoprim-sulfamethoxazole were used as a 
salvage treatment. The duration of antibiotic therapy 
varied markedly (median 16 weeks, range 6 weeks to 
2 years) (Table 2). 
 
 
 
Figure 2. Flow-chart for literature research. 
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Table 2. Treatment and follow-up. 
Patient No Implant 
Loosening 
Surgical 
Treatment 
Implant-free 
Interval (weeks) 
Antimicrobial Treatment 
and Duration (weeks) 
Good  
outcome 
Follow-up 
(years) 
  
References 
1 no none  Dox/Rif 76w yes 1.5 1 
2 no DAIR (arthroscopy)  Dox/Rif 6wk yes 1 2 (27) 
3 no none  Strep(2w)/Dox 106w yes 5 3 
4 yes one-stage exchange  Strep(1.5w)/Doxy/Rifa 25.5 w yes 3 3 
5 yes two-stage exchange 24 Dox/Rif 20w yes 2 4 (26) 
6 yes two-stage exchange 6 Dox/Rif 12 w yes 10 5 
7 no none  Dox/Rif 16w yes 3 6 
8 no none  Dox/Rif 6.5w; then Strep(3w)/Dox 12w yes <1 7 
9 no two-stage exchange 24 na na na 8 
10 no one-stage exchange  Tet 6w, then Tet 24w, then Strep(6w)/Tet 58w yes 2 9 
11 yes two-stage exchange 12 Dox/Rif 12w yes 10 10 
12 yes one-stage exchange  Dox/Rif 20w yes 4 11 
13 yes two-stage exchange 8 Gen(3w)/Dox/Rif 25w, then Dox/Rif/Bact >52w yes <1 12 
14 no none  Gen(2w)/Dox/Rif 24w yes 1 13 
15 na na  na na na 14 
16 no none  Strep(3w)/Dox 20w, then Bact 8w yes 2 15 
17 yes two-stage exchange 12 Dox/Rif 12 w yes 1.5 16 
18 yes Implant removal  Strep/Dox 4w, then Dox/Rif/Levo 32w yes < 1 17 
19 yes two-stage exchange 20 Dox/Rif 16w yes 2 18 
20 yes two-stage exchange 16 Strep/Dox/Rif 12w yes <1 19 
21 no none  Strep/Dox/Rif 6w yes <1 20 
22 yes two-stage exchange 16 Dox/Rif 6w yes 5.5 21 
23 no DAIR  Strep(6w)/Dox/Rif 24w yes 5 21 
24 no none  Dox/Rif 8w yes 1 22 
25 yes two-stage exchange 8 Strep(2w)/Dox/Rif 8w yes 4 23 
26 yes two-stage exchange 6 Dox/Rif 12 w yes 1 24 
27 yes two-stage exchange 6 Dox/Rif 12 w yes 1 24 
28 yes two-stage exchange 6 Dox/Rif 12 w yes 1 24 
29 yes one-stage exchange  Dox/Rif 24 w yes 1.5 25 
30 yes two-stage exchange 2.5 Dox/Rif/Pen 24w  yes 2 this case 
Strep: Streptomycin; Gen: Gentamicin; Dox: Doxycycline; Rif: Rifampin; Bact: Trimethoprim-Sulfamethoxazole; Levo: Levofloxacin; Tet: Tetracycline; Pen: Penicillin G; 
DAIR: debridement, antibiotics, irrigation and retention. 
 
Discussion 
The preoperative diagnosis of Brucella PJI is a 
challenge in non-endemic countries, mainly because 
of the rarity of the disease, and hence, lack of clinical 
experience. The microbiological analyses of synovial 
fluid in patients with suspected PJI is part of the 
routine diagnostic procedure in many centers. In case 
of Brucella PJI, however, this intervention – without 
the required aerosol precautions – may expose 
personnel both in the operating room and 
microbiology laboratory to the pathogen [28]. In 
contrast, serological tests for brucellosis in previously 
untreated patients and in non-endemic region are 
reliable and safe diagnostic tools [29]. Our and all 
reported cases revealed significant elevated 
anti-Brucella-antibodies. Thus, it is conceivable to 
think of brucellosis and perform serological tests prior 
to synovial puncture, when the patient history (e.g., 
exposure to unpasteurized dietary products) or his 
ethnicity points towards this differential diagnosis.  
In cases of suspected or confirmed Brucella PJI, 
infection control precautions are necessary prior to a 
surgical intervention. Laboratory staff must be 
pre-informed about potential growth of Brucella spp. 
when biopsy samples are sent for analyses [14, 28, 30]. 
Our literature review indicates that cultures of 
intra-operative tissue samples provide the best yield.  
There is no uniform recommendation for the 
surgical procedure in Brucella PJI. Loose implants 
must be exchanged, and successful outcomes with 
both one-stage and two-exchanges have been 
reported. Although a wide range of time periods for 
the implant-free interval have been reported (i.e., 6 
weeks to 6 months), we were unable to find a 
scientific rational against a short interval. Although, 
Brucella spp. have shown to form Biofilm in vitro [31, 
32], to the best of our knowledge, there are no reports 
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on Brucella-associated biofilm production on 
orthopedic implants. Thus, the clinical significance of 
in-vitro results requires further investigations. The 
overall good prognosis of Brucella PJI irrespective of 
applied treatment concept supported our surgical 
concept of a short interval.  
Antimicrobial treatment for brucellosis requires 
a combination regimen, because high relapse rates 
have been reported with monotherapy. Rifampin, 
doxycycline, ciprofloxacin, trimethoprim- 
sulfamethoxazole and aminoglycosides have good 
activity against brucellosis. Antimicrobial drug 
resistance is unusual but can be determined by the 
Etest method [33]. Doxycycline plus streptomycin or 
doxycycline plus rifampin are the most 
commonly-used combinations [34-36]. Given the side 
effects of aminoglycosides, in particular in the elderly, 
we prefer not to use gentamicin or streptomycin for a 
prolonged treatment period.  
It may be reasonable to start antimicrobial 
treatment prior to surgical intervention to lower the 
bacterial load, provided that Brucella spp. and other 
microorganisms are isolated from a preoperative joint 
puncture. In 10% of the described cases, a 
polymicrobial infection was reported. In retrospect, P. 
acnes may have been missed in our case. 
The optimal treatment duration in Brucella PJI is 
unknown. In brucellosis, irrespective of infection site, 
less than 6 weeks with monotherapy is associated 
with failure [37]. In analogy to treatment 
recommendation for brucellar spondylitis, we 
targeted a combination therapy of at least 12 weeks 
[35].  
Conclusions 
Brucella PJI is rare, and the diagnosis is often 
unexpected in non-endemic countries. Thinking of 
risk factors and ethnicity is the key to the diagnosis. 
Serological tests should be performed prior to joint 
puncture or surgical interventions. In case of positive 
anti-Brucella-antibodies, infection control must be 
involved and laboratory personnel informed prior to 
obtaining samples. Our review of the literature 
indicates that the prognosis is good, irrespective of 
surgical treatment modality. In rare cases, a 
polymicrobial infection can occur. On the basis of 
these data, and with respect to a shorter 
hospitalization period and better joint function, we 
prefer either a one-stage exchange or a two-stage 
exchange with a short interval in case of loose 
implants. A combination antimicrobial regimen is 
recommended, though, the optimal treatment 
duration is unknown. In our case, a 3-month course of 
doxycycline plus rifampin, followed by a 3 
month-course of doxycycline monotherapy showed a 
successful outcome. 
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